Brief Reports
Early Access
Domain-specific Skindex-29 response under biologics, conventional systemics, and phototherapy: a four-time-point real-world brief report
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 22 September 2026
86
Views
70
Downloads
Authors
Skindex-29 provides a domain-specific assessment of quality-of-life (QoL) burden in psoriasis, but real-world comparisons across treatment modalities and clinically relevant time points remain limited. We prospectively followed 183 adults with psoriasis (Psoriasis Area Severity Index [PASI]>10) treated with phototherapy, conventional systemic agents, or biologics in a tertiary center. Skindex-29 total and domain scores were assessed at weeks 0, 4, 12, and 16. Total scores decreased significantly within all modalities (all p<0.001), with earlier and larger observed reductions among patients receiving biologics. After Benjamini-Hochberg adjustment, between-group differences remained significant for total scores at weeks 0, 4, and 16; for Emotions and Functioning at weeks 0, 4, and 16; and for Symptoms at week 4. PASI was strongly correlated with all domains (r=0.692-0.795; all p<0.001). Skindex-29 may complement PASI in domain-aware monitoring, although the non-randomized design precludes causal interpretation.
Downloads
Download data is not yet available.
Citations
1. Barbieri JS, Gelfand JM. Patient-Reported Outcome Measures as Complementary Information to Clinician-Reported Outcome Measures in Patients With Psoriasis. JAMA Dermatol 2021;157:1236-7.
2. Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012;30:231-36.
3. Prinsen CA, Lindeboom R, Sprangers MA, et al. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol 2010;130:1318-22.
4. Sampogna F, Tabolli S, Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol 2012;92:299-303.
5. Lee YW, Park EJ, Kwon IH, et al. Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. Ann Dermatol 2010;22:389-96.
6. Ghezzi G, Costanzo A, Borroni RG. Health-Related Quality of Life in Psoriasis: Literature Review. J Clin Med 2024; 13:4623.
7. Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges 2021;19:934-150.
8. Reich K, Augustin M, Thaçi D, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol 2020;182:869-79.
9. Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol 2021;185:1135-45.
10. Gelfand JM, Armstrong AW, Lim HW, et al. Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatol 2024;160:1320-8.
11. Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatol Ther
(Heidelb) 2021;11:235-52.
12. Lebwohl M, Strober B, Schrader A, et al. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs Real World Outcomes 2024;11:451-64.
13. Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne) 2023;10:1243843.
14. Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol 2020;34:1174-85.
15. Milidrag A, Safiye T, Gutić M, et al. The Influence of Treatment Modalities on the Quality of Life of Psoriasis Patients. Iran J Public Health 2023;52:1925-34.
16. Augustin M, Barker J, Conrad C, et al. Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life. Dermatol Ther (Heidelb) 2025;15:1915-29.
17. Augustin M, Gottlieb AB, Lebwohl M, et al. Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatol Ther (Heidelb) 2024;14:2841-57.
Supporting Agencies
This study was funded by Junior Research Project JP08/22, “The impact of phototherapy on quality of life in psoriasis” (Faculty of Medical Sciences, University of Kragujevac). The funder had no role in study design, data collection, analysis, interpretation, manuscript preparation, or the decision to submit for publication.How to Cite
1.
Domain-specific Skindex-29 response under biologics, conventional systemics, and phototherapy: a four-time-point real-world brief report. Dermatol Reports [Internet]. 2026 Sep. 22 [cited 2026 Oct. 18];. Available from: https://journals.pagepress.net/dr/article/view/10651
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
